Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Biotech Companies Ailing, in Need of Cash Transfusion


Credit crunch putting the squeeze on drug research and development.

The credit crunch is likely to slow development of the next round of innovative drugs and change the way the pharmaceutical industry is structured.

Venture-capital firms are reducing their biotech investments, and venture-backed IPOs have just about dried up, and opportunities for bank loans are shrinking. A diminished biotech sector is bad news for major pharmaceutical companies, who depend on start-ups to invent new drugs that the giants then acquire and market.

Bankruptcies will result in further consolidation of the industry. There also will be layoffs in those biotechnology companies that survive.

The Biotechnology Industry Organization, a trade group in Washington, says 38% of 370 small biotech companies in the US operate with less than year's cash on hand. About 100 publicly traded biotech companies have less than 6 months' cash.

The stock of major biotech companies, including Amgen (AMGN), Genentech (DNA) and Gilead Sciences (GILD), have taken a hit, but the companies have deep revenue streams and should be able to carry them through the downturn.

GlaxoSmithKline (GSK) says it may acquire selected small drug companies now that the market has clipped their stock, making the take-out price attractive. Novartis (NSRGY) is also keeping an eye on the situation, The Wall Street Journal reports.

To secure funding, some companies are selling a portion of what they hope will be a drug's future revenue stream to investment firms. This is an expensive way to raise money, and a desperate move in the cash-starved capital markets.

Other firms are narrowing the scope of research. Cytokinetics plans to dump its work on cancer and focus of a drug for heart failure. About 29% of its workforce will be cut.

Atherogenics filed earlier this month for Chapter-11 bankruptcy protection after the company couldn't make debt payments in September. The company planned to begin trials of a diabetes drug before the money ran out. Atherogenics may sell the drug to another company that will bring it to market if clinical tests are successful.

Transcept Pharmaceuticals plans to merge with publicly held Novacea (NOVC) whose late-stage cancer drug failed recent tests. Assuming the merger is completed, Transcept Pharmaceuticals will retain control of the combined company and approval and commercialization efforts for Intermezzo, the company's lead drug candidate for the treatment of middle-of-the night awakenings.

Biotech companies have the potential to change the way we live, and a slowdown in development of new drugs could have far-reaching consequences.

What are the pro traders saying about your stocks?
Minyanville's Buzz & Banter- 14 day FREE Trial

< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos